Mizuho Medy Co.,Ltd. (4595.T) JPX
Currency In JPY
- General
- Statistics
- Historical Data
- Profile
- Financials
Currency In JPY
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
187
First IPO Date
December 18, 2015
| Name | Title | Pay | Year Born |
| Kenji Narahara | GM of Development Department & Director | 0 | 1963 |
| Toshio Kamihara | GM of Sales Division & Overseas Business Department and Director | 0 | 1964 |
| Takahiro Furuno | Executive Officer & Manager of Manufacturing Department | 0 | N/A |
| Fuminari Karakawa | Chairman of the Board & President | 0 | 1945 |
| Kazuhiro Ichimaru | GM of Intellectual Property & Manufacturing Department and Director | 0 | 1960 |
Established in 1977 and headquartered in Tosu, Japan, Mizuho Medy Co.,Ltd. specializes in the research, development, production, and distribution of in-vitro diagnostic solutions, complemented by scientific and technical information services. While its primary operations are in Japan, the company maintains an international presence through import and export activities, extending its reach to countries including the United States, Belgium, Finland, the Netherlands, Taiwan, and Thailand. Its extensive product lineup includes a wide array of immunoassay test kits designed for detecting pathogens such as influenza viruses, RS virus, human metapneumovirus, Streptococcus pneumoniae, Legionella, Mycoplasma pneumoniae, adenovirus, rotavirus, norovirus, and Group A streptococcus. Additionally, Mizuho Medy offers kits for pregnancy, ovulation, and fecal occult blood screening. The company also provides advanced tools like gene analysis instruments and specialized diagnostic kits for SARS-CoV-2 detection and Mycoplasma pneumoniae nucleic acid analysis.